Retatrutide
Retatrutide
Research into retatrutide — a triple GIP, GLP-1 and glucagon receptor agonist — has produced some of the most significant metabolic results seen in clinical history. Phase 2 human trials demonstrated weight reductions of up to 24.2% over 48 weeks alongside improvements in blood pressure, HbA1c, waist circumference and triglycerides. Studies suggest that activating three complementary metabolic hormone receptors simultaneously produces broader benefits to body composition and cardiometabolic health than single or dual receptor approaches.
Supplied as research-grade lyophilised peptide. Requires reconstitution with bacteriostatic water prior to use. For research purposes only.
Research Stack Builder
Build Your Research Stack
Curated combinations based on what researchers actually stack — backed by published data, priced to save.
Stack with Retatrutide
Why researchers stack these
- 01Triple non-competing fat loss pathways
- 02Skin integrity preserved during recomp
- 03AMPK activation for insulin sensitivity
Full research context
Retatrutide drives broad fat reduction via triple receptor agonism (GIP/GLP-1/glucagon). Tesamorelin adds a direct GH axis mechanism specifically targeting visceral adipose — FDA-approved and mechanistically distinct. GHK-Cu is consistently added once body recomposition is underway because rapid fat loss without collagen support produces visible skin laxity. MOTS-c completes the stack through AMPK activation and improved insulin sensitivity, addressing the metabolic efficiency component that neither GLP-1 nor GH axis mechanisms fully cover.
Recovery & Repair Protocol
The most studied peptide combination for tissue repair, injury recovery & musculoskeletal healing
Why researchers stack these
- 01Non-competing structural repair pathways
- 02BPC-157 angiogenesis + TB-500 satellite cell activation
- 03GHK-Cu adds the extracellular matrix layer both lack
Full research context
BPC-157 and TB-500 are the two most frequently co-researched repair peptides in published literature, acting through complementary mechanisms — BPC-157 via nitric oxide pathways and angiogenesis, TB-500 via actin-sequestering and satellite cell activation. GHK-Cu rounds out the stack by supporting collagen synthesis and the extracellular matrix that both compounds do not directly address, while reducing the oxidative load that slows tissue recovery.
Metabolic & Body Recomposition
Most popular Peptide Pal stack — two non-competing fat loss axes with skin integrity support
Why researchers stack these
- 01GLP-1 triple agonism + GH axis — two distinct fat loss pathways
- 02Skin integrity preserved throughout recomposition
- 03Most purchased together on Peptide Pal
Full research context
Retatrutide and Tesamorelin address body composition through two non-competing mechanisms. Retatrutide's triple receptor agonism drives broad metabolic improvement and appetite regulation; Tesamorelin is FDA-approved for visceral adipose reduction through the growth hormone axis — a distinct mechanism. GHK-Cu supports skin integrity during recomposition; rapid fat loss without collagen support produces visible skin laxity that is far harder to address after the fact.
Cognitive Performance Stack
Neuropeptides studied for synergistic cognitive enhancement, focus & stress resilience — no sedation
Why researchers stack these
- 01BDNF stimulation balanced by GABA modulation
- 02Focus without anxiety — three non-competing pathways
- 03NAD+ fuels the neuronal energy demand
Full research context
Semax and Selank are registered pharmaceuticals with distinct mechanisms. Semax drives BDNF upregulation and cortical processing speed; Selank reduces the stress-induced cognitive interference that can blunt that effect, without sedation or dependency. NAD+ provides the cellular energy substrate that enhanced neuronal activity demands — researchers consistently report that this combination delivers balanced cognitive performance that neither compound achieves alone.
Skin & Glow Protocol
Collagen synthesis, antioxidant protection & melanin research in one comprehensive skin stack
Why researchers stack these
- 01Collagen, antioxidant & pigmentation — three skin pillars
- 02Tyrosinase inhibition counterbalances MC1R agonism for pathway research
- 03Structural integrity maintained alongside brightening
Full research context
GHK-Cu stimulates collagen synthesis and modulates over 4,000 genes involved in skin repair and inflammatory control — addressing the structural layer. Glutathione reduces oxidative stress and inhibits tyrosinase, producing measurable skin brightening with 30–35% tissue GSH increases confirmed in human RCTs. MT2 drives eumelanin synthesis via MC1R agonism, and researchers frequently combine it with Glutathione to study the interplay between melanocortin-driven pigmentation and tyrosinase inhibition simultaneously. Together these three represent the most comprehensive skin research protocol available.
Cellular Longevity Protocol
Three compounds that decline together with age — combined restoration for mitochondrial & cellular health
Why researchers stack these
- 01All three decline together with age — parallel restoration
- 02Mitochondrial energy, AMPK signalling & antioxidant protection
- 03Most complete cellular longevity protocol available
Full research context
NAD+, MOTS-c, and glutathione all decline measurably with age through parallel but distinct pathways. NAD+ restores sirtuin and PARP function essential for mitochondrial biogenesis and DNA repair — declining up to 50% by age 60. MOTS-c is the mitochondria-derived peptide that activates AMPK signalling and declines alongside NAD+; their combined restoration is the most researched longevity intervention. Glutathione provides the antioxidant protection that prevents cellular damage during the heightened metabolic activity that NAD+ and MOTS-c restoration drives — completing what researchers describe as the foundational cellular longevity triad.
Research & Studies
Peer-reviewed research supporting Retatrutide
Retatrutide Phase 2: Up to 24.2% Body Weight Reduction in Human Clinical Trial
A Phase 2 randomised trial in 338 adults with obesity demonstrated that once-weekly retatrutide — a triple GIP, GLP-1, and glucagon receptor agonist — produced dose-dependent reductions in body weight of up to 24.2% at 48 weeks at the 12mg dose, far exceeding the efficacy of existing approved single or dual receptor agonists. The 17.5% reduction seen at 24 weeks was already greater than the 48-week results of prior agents. These human trial results established retatrutide as the most potent weight-loss compound tested in Phase 2 clinical research at the time of publication, supporting its progression into Phase 3 trials.
Retatrutide Reduces HbA1c, Blood Pressure and Triglycerides: Phase 2 Cardiometabolic Outcomes
Beyond headline weight loss, the Phase 2 human trial documented comprehensive cardiometabolic improvements as secondary endpoints. At the 15mg dose, participants showed reductions in waist circumference of up to 13.9cm, systolic blood pressure reductions of 4–7 mmHg, significant decreases in fasting triglycerides, and reductions in HbA1c of up to 2.02 percentage points in the type 2 diabetes subgroup — moving many from diabetic into normoglycaemic status. Improvements in fasting glucose, liver enzyme markers, and LDL profiles were also recorded, demonstrating broad-spectrum metabolic risk reduction in humans beyond weight loss alone.